Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

ACTON, Mass., November 20, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of ...

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S. Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $305.00. The ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated ...

ACTON, Mass., November 20, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products ...